The annual report of Sinopharm group in the first half of the year has been published, with an operating revenue of 21.012 billion yuan

On Tuesday, Sinopharm group released its annual report for the first half of 2019 The company's operating revenue reached 21.012 billion yuan, an increase of 11.99% year-on-year The net profit attributable to shareholders of listed companies was 755 million yuan, an increase of 18.66% year-on-year, achieving rapid development Among them, the implementation of the strategic plan of Sinopharm group in the first half of the year is selected for your reference: (1) plan for strategic transformation During the reporting period, according to the current situation of the industry and changes in pharmaceutical policies, the company's management and relevant departments gradually improved the strategic positioning of Sinopharm, actively innovated and transformed the company, improved the company's structure, built the company's diversified core competitiveness, and realized the upgrading of the core strategy of Sinopharm Sort out and draft the strategy of three sub sectors of Sinopharm, formulate detailed planning rules, and sort out the upper structure design of subsidiaries （2） Business transformation is underway 1 In the first half of the year, the company's anesthetics business entered into the "big anesthetics" mode The company introduced a number of first-class and second-class psychotropic drugs, expanded the field of anesthetics, deepened its absolute advantages, introduced new clinical products of Mengdi, and discussed new field cooperation with partners Discuss cooperation with many medical equipment enterprises on narcotics cabinet for medical use; rely on the mature seal card management system, actively expand the "narcotics cabinet" project, and start to try the hospital management of narcotics in secondary and county-level medical units 2 The company's direct marketing business actively developed the community innovative service reporting period, participated in the sugar screening of diabetes patients in the pilot community, connected with the manufacturer's resources, participated in the oral cavity caries prevention project, and participated in the health advisory project of the Health Committee of multiple associations 3 The company's procurement business strengthened the introduction of new imported products in the reporting period The company strengthened the introduction of new imported products, newly introduced Weicai hailewai (breast cancer treatment), Huaxi botulinum toxin, etc., and Pfizer Renjie and Beifu added new specifications; developed 15 varieties of innovative drugs; completed the key work of account opening, purchase and marketing linkage of key manufacturers 4 Subsidiaries should respond to policy and market changes, accelerate business adjustment, and strengthen community academic investment Sinopharm Technology: as a regional integrated service provider and implementation platform in Beijing, it strives to create a new business model of "product + service" and gradually promotes the improvement of the company's upper structure design Guokong Shengyuan: adjust business structure, expand supplier cooperation, and vigorously expand non hemp and non refined drugs 5 Guorui pharmaceutical, a holding subsidiary, speeds up its transformation During the reporting period, Guorui pharmaceutical industry made rapid progress in the consistency evaluation of azithromycin for injection; deepened the marketing transformation to the integration of learning and marketing, and the integration of control and marketing, with the sales director directly in charge of all provinces and regions, and gradually cancelled the provincial agent to face the terminal medical units; vigorously carried out academic activities to achieve the sales increase; cooperated with foreign trade companies to carry out the injection of related varieties in foreign countries Volume work, the raw materials of pyrrolimus potassium and edaravone are exported to South Korea and Ukraine respectively, laying a solid foundation for Guorui pharmaceutical industry to undertake international orders in the future 6 Adapt to the development of the industry, base on the long-term planning, and continuously innovate and develop the logistics industry Sinopharm Logistics: during the reporting period, it actively expanded the third-party equipment service and introduced a new equipment owner; improved the quality standard and warehousing operation process of Yongqing warehouse, realized the two-way docking of the old and new systems, and laid the foundation for the subsequent operation; completed the AGV project of China Post warehouse, and improved the operation efficiency; and was awarded the "national standard pilot enterprise" in the code for the operation of pharmaceutical cold chain logistics (GB / t28842-2012) Title Sinopharm Airport: overcome the adverse effects of policy factors and market environment, develop new businesses such as proprietary clotrimazole APIs, scientific instruments, reference preparations, etc.; continue to maintain the competitive advantage of new product import inspection effectiveness in the industry Guokong Huahong: signed a contract with Jingdong Logistics to build a new medical warehouse with high standards; the transformation and installation of relevant facilities are in progress to ensure the smooth progress of the relocation of the logistics warehouse 7 The equipment business of the subsidiary company continued to expand Guokong Huahong successfully won the bid for the centralized procurement project of equipment innovation service in large hospitals, and continued to improve the service level of the supply chain Guokong Tianxing: vigorously develop direct sales of equipment products Sinopharm science and technology: the project of the stock hospital is constantly optimized; actively try the business direction of equipment bidding and consumables distribution, and start the consumables distribution business 8 Sustained development of blood products, academic promotion, e-commerce and other characteristic businesses guokong Kangchen and guokong Tianxing continue to highlight the operating characteristics of blood products and continue to expand the market share of blood products Guokong Huahong's marketing business complies with the changes of pharmaceutical policies to ensure the sound development of advantageous varieties; it increases cooperation with domestic marketing enterprises to strengthen the market coverage and variety penetration capacity of influenza kits and other marketing varieties through subcontracting, joint promotion, etc The company's e-commerce sector actively implemented the expansion of passenger flow, improvement of service and transformation, organized group purchase of products, implementation of training platform, cooperation in financial instruments, and introduced new oral products in the first half of the year 9 In the report period of strategic transformation, guokong Tianxing purchased 70% equity of Beijing Huixin Qingyuan science and Technology Development Co., Ltd to expand the sales path of guokong Tianxing in organ transplantation field, further enrich the company's product line and tap new profit growth points During the reporting period, the company explored the possibility and implementation path of new retail stores, and conducted on-site research on potential addresses （3） Improve management to match the transformation and development of the company 1 Strengthen the management of accounts receivable and highly prevent credit risks 2 Steadily promote regional integration in accordance with the overall planning and deployment 3 Strengthen risk prevention and control, improve comprehensive management and support the development of the company 4 Promote process optimization and management informatization and improve business efficiency; 5 Improve the environment, adjust performance, and form a new spiritual outlook and positive value orientation of motivation （4） Thinking transformation and innovation deeply rooted in people's hearts 1 As the first batch of pilot units of mixed reform, the mechanism transformation and innovation company actively explored the pilot methods and steadily promoted the work related to mixed reform of the company in combination with its own characteristics 2 During the capital driven innovation reporting period, in order to improve the efficiency of the use of raised funds, the company started to use some idle raised funds to temporarily replenish the working capital, with the total amount of temporary replenishment not exceeding 854 million yuan Up to now, the company has used 775 million yuan of raised funds to temporarily supplement the working capital 3 Actively introduce the report period of innovation projects, actively explore innovation fields such as medical terminal solutions and device services, introduce new partners, and strive to achieve innovation breakthroughs in the main business （5） Respond to policy changes and adjust market strategies 1 Pay close attention to the new policy of centralized drug procurement organized by the state The company attaches great importance to "4 + 7" centralized mining, and under the overall planning, through comprehensive follow-up, organization and negotiation, rapid landing, exclusive account opening, etc., to ensure that the first centralized mining authorization, sales and account opening have achieved good results; Beijing has a total of 40 product specifications, and the company ranks the first with 35 product distribution authorization; the company has in-depth cooperation with two winning enterprises, Shanghai anbisheng and Zhejiang Jingxin, to obtain Exclusive distribution qualification of montelukast sodium tablets and rosuvastatin calcium tablets (10mg) in Beijing 2 In the first half of this year, 123 new drugs (including innovative drugs and generic drugs) have been approved for listing, and 42 companies have cooperated with each other, bringing incremental growth to the company's development Appendix: Sinopharm group's annual report for the first half of 2019.pdf this article is the content reprinted by yaozhi.com, and the copyright belongs to the original author The purpose of reprinting is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.